WebbTheradiag lance une augmentation de capital avec maintien du droit préférentiel de souscription Montant cible de 5,33 millions d'euros Prix de souscription : 1,22 € par … Webb25 nov. 2024 · Theradiag : augmentation de capital réussie 25/11/2024 08:58 Theradiag annonce le succès de son augmentation de capital avec maintien du DPS dont la …
Theradiag: augmentation de capital réussie - ABC Bourse
WebbFör 1 dag sedan · THERADIAG. Biosynex SA (ENXTPA:ALBIO) completed the acquisition of additional 46.52% stake in Theradiag SA (ENXTPA:ALTER) for €21.6 million. Theradiag develops, produces, and sells in vitro diagnostic kits for detecting auto-immune diseases, allergies, and infectious diseases. The group also offers theranostic tests for monitoring ... Webb23 sep. 2024 · Theradiag announces that Biosynex has filed a. voluntary takeover bid for its shares. Croissy-Beaubourg (France), September 23, 2024, 1.45 pm CEST - THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, announces that. Biosynex (ISIN: FR0011005933 - Mnemonic: ALBIO) has … portsmouth stormwater maintenance facilities
Theradiag veut lever 5 millions d’euros et perd plus de 20 ... - Investir
WebbTheradiag has raised a total of €18.9M in funding over 4 rounds. Their latest funding was raised on Nov 26, 2024 from a Post-IPO Equity round. Theradiag is registered under the ticker EPA:ALTER . Theradiag is funded by 8 investors. Auriga Partners and Siparex Groupe are the most recent investors. Theradiag has acquired Prestizia on Jun 27, 2012. Webb1 mars 2024 · The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2024, the Company posted revenue of €12.2 million. The Theradiag share is... WebbTheradiag commercialise la gamme LISA TRACKER®, marquée CE, une solution complète de diagnostic multiparamétrique pour la prise en charge des patients atteints de maladies auto-immunes et traités... oracle based applications